다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Annals of the rheumatic diseases : the official journal, v.73 no.3, 2014년, pp.595 - 599
Yoshida, Kazuki (Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, , Boston, Massachusetts, USA) , Sung, Yoon-Kyoung (Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, , Boston, Massachusetts, USA) , Kavanaugh, Arthur (Division of Rheumatology, Allergy and Immunology, University of California, San Diego, , La Jolla, California, USA) , Bae, Sang-Cheol (Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, , Seoul, South Korea) , Weinblatt, Michael E (Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, , Boston, Massachusetts, USA) , Kishimoto, Mitsumasa (Division of Allergy and Rheumatology, St. Luke's International Hospital, , Chuo-ku, Tokyo, Japan) , Matsui, Kazuo (Department of Rheumatology, Kameda Medical Center, , Kamogawa, Chiba Prefecture, Japan) , Tohma, Shigeto (Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, , Sagamihara, Japan) , Solomon, Daniel H (Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, , Boston, Massachusetts, USA)
AI-Helper
ObjectivesWe conducted a systematic review to assess the design and ‘failure definition’ in studies of biologic discontinuation in rheumatoid arthritis (RA).MethodsWe found 403 studies on PubMed, and included nine published papers and five abstracts from scientific meetings. We used a ...
Lancet Smolen 381 918 2013 10.1016/S0140-6736(12)61811-X Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
Arthritis Rheum Chatzidionysiou 64 Suppl 10 S336 2012 A multicenter, randomized, controlled, open-label pilot study of the feasibility of discontinuation of adalimumab in rheumatoid arthritis patients in stable clinical remission [abstract]
Mod Rheumatol Harigai 22 814 2012 10.3109/s10165-011-0586-5 Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity
Ann Rheum Dis Smolen 71 Suppl 3 361 2012 10.1136/annrheumdis-2012-eular.2607 Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab pegol treatment: week 52 results from the CERTAIN study
Arthritis Rheum Van Vollenhoven 64 4171 2012 In rheumatoid arthritis patients with stable low disease activity on methotrexate plus etanercept, continuation of etanercept 50 mg weekly or 25 mg weekly are both clinically superior to discontinuation: results from a randomized, 3-armed, double-blind clinical trial [abstract]
Ann Rheum Dis Detert 2013 10.1136/annrheumdis-2012-201612 Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study
Arthritis Rheum Tanaka 64 Suppl 10 345 2012 Discontinuation of adalimumab without functional and radiographic damage progression after achieving sustained remission in patients with rheumatoid arthritis (the HONOR study): 1-year results [abstract]
Ann Rheum Dis Van der Maas 71 1849 2012 10.1136/annrheumdis-2011-200945 Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study
Rheumatology (Oxford) Kavanaugh 51(Suppl 3) iii27 2012 Withdrawal of adalimumab in early rheumatoid arthritis patients who attained stable low disease activity with adalimumab plus methotrexate: results of a phase 4, double-blind, placebo-controlled trial
Ann Rheum Dis Van den Broek 70 1389 2011 10.1136/ard.2010.147751 Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study
Ann Rheum Dis Tanaka 69 1286 2010 10.1136/ard.2009.121491 Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Joint Bone Spine Brocq 76 350 2009 10.1016/j.jbspin.2008.11.009 Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis
Mod Rheumatol Nawata 18 460 2008 10.3109/s10165-008-0089-1 Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission
Arthritis Rheum Quinn 52 27 2005 10.1002/art.20712 Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial
Arthritis Rheum Bruynesteyn 46 913 2002 10.1002/art.10190 Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference
Ann Rheum Dis Bartlett 71 1855 2012 10.1136/annrheumdis-2011-201201 Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 공개 리포지터리에 출판본, post-print, 또는 pre-print를 셀프 아카이빙 하여 자유로운 이용이 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.